Osteopenia and Renal Osteodystrophy: Evaluation and Management
Osteopenia, Renal Osteodystrophy
About this trial
This is an interventional treatment trial for Osteopenia focused on measuring Uremia, Dialysis, Clinical Trials, Bone Diseases, Metabolic, adynamic bone disease, low bone turnover
Eligibility Criteria
Inclusion Criteria: Dialysis dependent for a minimum of 3 months Age greater than 18 years Low or normal bone turnover as defined by a mean intact PTH ≤400 pg/ml from a minimum of two values 6 months apart Informed consent Exclusion Criteria: Mean serum aluminum levels > 20 mcg/L during 1 year prior to consent Documented dementia Comorbidity such that survival for >3 years is unlikely Use of steroids within 3 months of consent Use of bisphosphonates in previous 2 years Use of sex hormones (testosterone or estrogen) within 3 months of consent Mean calcium < 9.0 mg/dL during the two months prior to consent Peritoneal dialysis patients Body weight < 45 kg
Sites / Locations
- VA Puget Sound Health Care System